Adverse Effects of ATG/ALG Therapy in Aplastic Anemia
ConditionAplastic Anaemia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorInstitute of Hematology & Blood Diseases Hospital, China
About this trial
This prospective, single-center, observational cohort study aims to systematically observe and describe the clinical characteristics of adverse reactions in patients with aplastic anemia undergoing ATG (Anti-Thymocyte Globulin) /ALG (Anti-Lymphocyte Globulin) treatment, providing a data foundation for the development of relevant management strategies. This study plans to enroll 200 aplastic anemia patients undergoing ATG/ALG treatment
Eligibility criteria
Qualifiers
Meet the diagnostic criteria for aplastic anemia (Camitta criteria);
Receiving ATG/ALG immunosuppressive therapy for the first time;
Disqualifiers
Previously received hematopoietic stem cell transplantation;
Aplastic anemia patients receiving ATG/ALG as part of transplant conditioning regimen;
Trial design
Treatments tested in this trial
- ATG/ALG
Treatment groups
200 Participants
are divided into 1 treatment groupLocations
1Regenerative Medicine Center and Red Blood Cell Disorders Center Tianjin China
Sponsors and collaborators
Institute of Hematology & Blood Diseases Hospital, China
Lead sponsor
Source ClinicalTrials.gov